The objective of the study is to assess the effect of food on the pharmacokinetics, and safety of Fuzuloparib Capsules in healthy subject.
Study Type
INTERVENTIONAL
Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Enrollment
20
Fuzuloparib Capsules; 150mg; single dose per cycle.
Wannan Medical College Yijishan Hospital
Wuhu, Anhui, China
Maximum Plasma Concentration (Cmax)
Time frame: day 1 to day 10
Area under the plasma concentration versus time curve from time 0 to last time of measurable concentration (AUC0-t)
Time frame: day 1 to day 10
Area under the plasma concentration versus time curve from time 0 to infinity (AUC0-∞ )
Time frame: day 1 to day 10
The incidence and severity of adverse events/serious adverse events
Time frame: from ICF signing date to approximate day 23
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.